Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis
Targeting specific pathologic pro-inflammatory cytokines or related molecules leads to excellent therapeutic effects in inflammatory arthritis, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Most of these agents, known as biologic disease-modifying anti-rheumatic dr...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/22/13913 |
| _version_ | 1797465143867604992 |
|---|---|
| author | Hong Ki Min Se Hee Kim Hae-Rim Kim Sang-Heon Lee |
| author_facet | Hong Ki Min Se Hee Kim Hae-Rim Kim Sang-Heon Lee |
| author_sort | Hong Ki Min |
| collection | DOAJ |
| description | Targeting specific pathologic pro-inflammatory cytokines or related molecules leads to excellent therapeutic effects in inflammatory arthritis, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Most of these agents, known as biologic disease-modifying anti-rheumatic drugs (bDMARDs), are produced in live cell lines and are usually monoclonal antibodies. Several types of monoclonal antibodies target different pro-inflammatory cytokines, such as tumor necrosis factor-α, interleukin (IL)-17A, IL-6, and IL-23/12. Some bDMARDs, such as rituximab and abatacept, target specific cell-surface molecules to control the inflammatory response. The therapeutic effects of these bDMARDs differ in different forms of inflammatory arthritis and are associated with different adverse events. In this article, we summarize the therapeutic utility and adverse effects of bDMARDs and suggest future research directions for developing bDMARDs. |
| first_indexed | 2024-03-09T18:17:21Z |
| format | Article |
| id | doaj.art-115b411fa5114d2997cf0456654f581a |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T18:17:21Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-115b411fa5114d2997cf0456654f581a2023-11-24T08:35:29ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-11-0123221391310.3390/ijms232213913Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory ArthritisHong Ki Min0Se Hee Kim1Hae-Rim Kim2Sang-Heon Lee3Division of Rheumatology, Department of Internal Medicine, Konkuk University Medical Center, Seoul 05030, KoreaDivision of Rheumatology, Department of Internal Medicine, Konkuk University Medical Center, Seoul 05030, KoreaDivision of Rheumatology, Department of Internal Medicine, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul 05030, KoreaDivision of Rheumatology, Department of Internal Medicine, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul 05030, KoreaTargeting specific pathologic pro-inflammatory cytokines or related molecules leads to excellent therapeutic effects in inflammatory arthritis, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Most of these agents, known as biologic disease-modifying anti-rheumatic drugs (bDMARDs), are produced in live cell lines and are usually monoclonal antibodies. Several types of monoclonal antibodies target different pro-inflammatory cytokines, such as tumor necrosis factor-α, interleukin (IL)-17A, IL-6, and IL-23/12. Some bDMARDs, such as rituximab and abatacept, target specific cell-surface molecules to control the inflammatory response. The therapeutic effects of these bDMARDs differ in different forms of inflammatory arthritis and are associated with different adverse events. In this article, we summarize the therapeutic utility and adverse effects of bDMARDs and suggest future research directions for developing bDMARDs.https://www.mdpi.com/1422-0067/23/22/13913monoclonal antibodybiologic disease-modifying anti-rheumatic drugrheumatoid arthritisspondyloarthritispsoriatic arthritisinflammatory arthritis |
| spellingShingle | Hong Ki Min Se Hee Kim Hae-Rim Kim Sang-Heon Lee Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis International Journal of Molecular Sciences monoclonal antibody biologic disease-modifying anti-rheumatic drug rheumatoid arthritis spondyloarthritis psoriatic arthritis inflammatory arthritis |
| title | Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis |
| title_full | Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis |
| title_fullStr | Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis |
| title_full_unstemmed | Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis |
| title_short | Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis |
| title_sort | therapeutic utility and adverse effects of biologic disease modifying anti rheumatic drugs in inflammatory arthritis |
| topic | monoclonal antibody biologic disease-modifying anti-rheumatic drug rheumatoid arthritis spondyloarthritis psoriatic arthritis inflammatory arthritis |
| url | https://www.mdpi.com/1422-0067/23/22/13913 |
| work_keys_str_mv | AT hongkimin therapeuticutilityandadverseeffectsofbiologicdiseasemodifyingantirheumaticdrugsininflammatoryarthritis AT seheekim therapeuticutilityandadverseeffectsofbiologicdiseasemodifyingantirheumaticdrugsininflammatoryarthritis AT haerimkim therapeuticutilityandadverseeffectsofbiologicdiseasemodifyingantirheumaticdrugsininflammatoryarthritis AT sangheonlee therapeuticutilityandadverseeffectsofbiologicdiseasemodifyingantirheumaticdrugsininflammatoryarthritis |